Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | ASN004 |
Synonyms | |
Therapy Description |
ASN004 is an antibody-drug conjugate (ADC) comprising an antibody that targets 5T4 (TPBG) linked to Auristatin F hydroxypropylamide, potentially resulting in cytotoxicity of tumor cells expressing 5T4 (TPBG), inhibition of tumor growth, and tumor regression (PMID: 34045226). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ASN004 | ASN 004|ASN-004 | ASN004 is an antibody-drug conjugate (ADC) comprising an antibody that targets 5T4 (TPBG) linked to Auristatin F hydroxypropylamide, potentially resulting in cytotoxicity of tumor cells expressing 5T4 (TPBG), inhibition of tumor growth, and tumor regression (PMID: 34045226). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04410224 | Phase I | ASN004 | Study of ASN004 in Patients With Advanced Solid Tumors (ASN004) | Active, not recruiting | USA | 0 |